IQVIA Stock News

PHILADELPHIA , Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Morgan Stanley Annual Healthcare Conference in New York on Wednesday, September 4, 2024 at 10:00 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations webs...

IQVIA Holdings Inc. stock is up following Q2 earnings, following business upsides across its portfolio. Q2 earnings showed strong performance in TAS and R&DS divisions, with a record backlog and increased guidance for FY'24. Implied valuations are corroborated at a $260/share price objective, with potential further technical upside to $283/share if momentum sustains.

IQVIA Holdings (IQV) beat second-quarter earnings expectations and raised its full-year outlook on Monday, sending shares higher.

IQVIA Holdings Inc. (NYSE:IQV ) Q2 2024 Earnings Conference Call July 22, 2024 9:00 AM ET Company Participants Kerri Joseph - SVP, IR & Treasury Ari Bousbib - Chairman & CEO Ron Bruehlman - EVP & CFO Conference Call Participants Shlomo Rosenbaum - Stifel David Windley - Jefferies Anne Samuel - JP Morgan Elizabeth Anderson - Evercore ISI Max Smock - William Blair Jailendra Singh - Truist Securit...

Iqvia stock bolted higher Monday after the contract research firm raised its outlook for the year on the back of unexpected strength.

Contract research firm IQVIA Holdings raised its forecast for full-year profit on Monday, banking on strength in demand for its healthcare data and analytics services.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2024. Second-Quarter 2024 Operating Results Revenue for the second quarter of $3,814 million increased 2.3 perc...